Results 221 to 230 of about 134,214 (298)

An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Patients with haemophilia A (HA) and haemophilia B (HB) are at increased bleeding risk. A recent guidance document suggests considering pharmacological thromboprophylaxis on a case‐by‐case basis in these patients undergoing surgery at high‐risk of venous thromboembolism.
Nicoletta Riva   +8 more
wiley   +1 more source

Disulfide bond status links the open and closed conformations of prothrombin

open access: yesProtein Science, Volume 35, Issue 12, December 2026.
Abstract Emerging evidence indicates that structural changes in proteins can influence autoimmune recognition. Antibodies targeting the central blood coagulation protein, prothrombin, are frequently detected in patients with the autoimmune disorder, antiphospholipid syndrome.
Mark Schreuder   +4 more
wiley   +1 more source

Prothrombinase processivity is conferred by substrate allostery. [PDF]

open access: yesEMBO J
Üstok FI   +3 more
europepmc   +1 more source

Genetic Spectrum of Cholestasis in Tunisia and Diagnostic Yield of Next‐Generation Sequencing: Case Series of 70 Patients

open access: yesClinical Genetics, Volume 110, Issue 6, Page 716-723, December 2026.
Genetic hepatic cholestasis: NGS diagnostic yield. Over a 10‐year period, NGS (gene panel/WES) established a genetic diagnosis in 70% of 66 families with hepatic cholestasis, with a molecular yield of 62%. ABCB11 was the most mutated gene, and PFIC Type 2 was the leading diagnosis, underscoring the critical role of NGS in guiding genetic counseling and
Amal Abdmouleh   +12 more
wiley   +1 more source

Apixaban Use Before Kidney Transplantation: Is Reversal Necessary? [PDF]

open access: yesPharmacotherapy
Cotiguala L   +11 more
europepmc   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11143-11177, December 2026.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding   +4 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1421-1441, December 2026.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy